Nektar Therapeutics (NASDAQ:NKTR)

CAPS Rating: 2 out of 5

A biopharmaceutical company which develops breakthrough products that make a difference in patients' lives. It creates differentiated, innovative products by applying its platform technologies to established or novel medicines.

Recs

1
Player Avatar fatmoneyrz (96.53) Submitted: 9/27/2013 10:11:36 AM : Outperform Start Price: $10.55 NKTR Score: -12.31

Buying opportunities like this don't come along often. NKTR is solid, some nice upcoming catalysts in late 2013.

Featured Broker Partners


Advertisement